Skip to main content
SpringerLink
Log in

Early awareness key to successful management of heparin-induced thrombocytopenia (HIT)

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Amiral J. Antigens involved in heparin-induced thrombocytopenia. Semin Hematol 1999; 36(1) Suppl. 1: 7–11

    PubMed  CAS  Google Scholar 

  2. Tardy-Poncet B, Tardy B. Heparin-induced thrombocytopenia: minimising the risks in the elderly patient. Drugs Aging 2000 May; 16(5): 351–64

    Article  PubMed  CAS  Google Scholar 

  3. McKeage K, Plosker GL. Argatroban. Drugs 2001: 61(4): 515–22

    Article  PubMed  CAS  Google Scholar 

  4. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis, frequency, avoidance and management. Drug Saf 1997; 17(5): 325–41

    Article  PubMed  CAS  Google Scholar 

  5. Alving MB, Krishnamurti C. Recognition and management of heparin-induced thrombocytopenia (HIT) and thrombosis. Semin Thromb Hemost 1997; 23(6): 569–74

    Article  PubMed  CAS  Google Scholar 

  6. Greinacher A, Amiral J, Dummel V. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test and platelet factor 4/heparin enzyme linked immunosorbent assay. Transfusion 1994; 34: 381–5

    Article  PubMed  CAS  Google Scholar 

  7. Hirsch J, Warkentin TE, Raschke R, et al. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114: 489S–510S

    Article  Google Scholar 

  8. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenes is of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804–12

    PubMed  CAS  Google Scholar 

  9. Lubenow N, Greinacher A. Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin. BioDrugs 2000 Aug; 14(2): 109–25

    Article  PubMed  CAS  Google Scholar 

  10. Tardy B, Tardy-Poncet B, Fournel P, et al. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost 1999; 82: 1199–200

    PubMed  CAS  Google Scholar 

  11. 2000 Drug Topics® Red Book®. Montvale (NJ): Medical Economics Company, Inc., 2000

  12. British National Formulary. No. 41. London: The Pharmaceutical Press, 2001 Mar: 115-6

  13. Wilde MI, Markham A. Danaparoid sodium: a review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997; 54(6): 303–24

    Article  Google Scholar 

  14. Adkins JA, Wilde MI. Lepirudin: a review of its potential place in the management of thrombotic disorders. BioDrugs 1998 Sep; 10(3): 227–55

    Article  PubMed  CAS  Google Scholar 

  15. Kondo LM, Wittkowsky AK, Wiggins BS. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Ann Pharmacother 2001 Apr; 35: 440–451

    Article  PubMed  CAS  Google Scholar 

  16. Warkentin TE. Argatroban: a viewpoint. Drugs 2001; 61(4): 523

    Article  Google Scholar 

  17. Walenga JM, Ahmad S, Hoppensteadt DA, et al. Prolonged argatroban treatment does not result in the generation of neutralizing antibodies [abstract]. XVIIth Congress of the International Society on Thrombosis and Haemostasis; 1999 Aug 14

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Early awareness key to successful management of heparin-induced thrombocytopenia (HIT). Drugs Ther. Perspect 17, 8–12 (2001). https://doi.org/10.2165/00042310-200117140-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117140-00003

Keywords

Search

Navigation